Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Swiss National Bank

Swiss National Bank cut its stake in Moderna, Inc. (NASDAQ:MRNA) by 4.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 923,000 shares of the company’s stock after selling 43,800 shares during the period. Swiss National Bank’s holdings in Moderna were worth $38,378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. State Street Corp increased its holdings in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Wellington Management Group LLP increased its holdings in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the period. Amundi increased its holdings in shares of Moderna by 79.8% during the fourth quarter. Amundi now owns 1,206,273 shares of the company’s stock valued at $52,075,000 after purchasing an additional 535,273 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Moderna during the third quarter valued at $23,825,000. Finally, Douglas Lane & Associates LLC increased its holdings in shares of Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after purchasing an additional 298,715 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Morgan Stanley lowered their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Leerink Partners lowered their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Argus lowered Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $59.60.

Moderna Trading Up 0.9 %

Shares of NASDAQ MRNA opened at $34.62 on Monday. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The firm has a market capitalization of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. The business has a 50-day moving average price of $35.94 and a two-hundred day moving average price of $47.15.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.